Search Results
Mar 17, 2026, 10:01 ET Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight
increasingly important, especially for previously incurable diseases. Due to the special immunomodulatory and anti-inflammatory properties, ABCB5+ mesenchymal stromal cells (ABCB5+ MSCs) represent a new, promising therapeutic approach for various chronic inflammatory diseases, including epidermolysis bullosa.Epidermolysis
More news about: DelveInsight Business Research, LLP
Feb 13, 2026, 18:01 ET Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression
cells. Notably, reduced deuterium levels (as low as 40 ppm) suppressed genes associated with proliferation and drug resistance (e.g., MYCN, ETS2, ABCB1), while high deuterium environments (300 ppm) upregulated multiple oncogenic and survival pathways (EGFR, CTNNB1, STAT3, CD44).The study confirmed
More news about: HYD LLC
Aug 12, 2025, 08:03 ET Banco ABC Brasil encerra 2º trimestre com alta no lucro
trimestreSÃO PAULO, 12 de agosto de 2025 /PRNewswire/ -- O Banco ABC Brasil (ABCB4) registrou lucro líquido recorrente de R$ 244,1 milhões no segundo trimestre de 2025, avanço de 8,2% sobre os três primeiros
More news about: Banco ABC Brasil
Jun 17, 2025, 10:00 ET Genomenon Powers Groundbreaking Study on Genetic Drivers of Rare Liver Disorders
Mike Klein, CEO of Genomenon.The peer-reviewed paper, titled "An ABCB11 variant registry and novel knockin mouse model of PFIC2 based on the clinically relevant ABCB11 E297G variant", introduces two powerful tools for advancing PFIC2 research: A knockin
More news about: Genomenon